Workshop on Combination Immunotherapy: Where Do We Go From Here?

The SITC 2014 Workshop Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc.

Access slide decks and video via the links in the schedule below.

PDF = click on presentation title to view .pdf version of slides.

VIDEO = presentation video is available. Click on the icon to view video. (Note: if no .pdf version is available for a given presentation, video will be linked from the presentation title.)

Thursday, November 6, 2014
7:00 am – 8:00 am Breakfast
8:00 am – 8:15 am Workshop Overview and the Current Immunotherapy Landscape
.25 AMA PRA Category 1 Credit™
8:00 am – 8:05 am Welcome and Overview
Drew M. Pardoll, MD, PhD – Johns Hopkins University
8:05 am – 8:15 am The Current Immunotherapy Landscape
Drew M. Pardoll, MD, PhD – Johns Hopkins University
8:15 am – 9:35 am Session I: Beyond the Inflamed/Non-Inflamed Classification of the Immune
Microenvironment
1.25 AMA PRA Category 1 Credit™
8:15 am – 8:35 am Immunoscore in the Era of Cancer Immunotherapies
Jerome Galon, PhD – INSERM - Cordeliers Research Center
8:35 am – 8:55 am Immune-Tumor Interactions to Guide Combination Therapies  PDF  VIDEO
Antoni Ribas, MD, PhD – University of California Los Angeles
8:55 am – 9:15 am PD-L1 IHC in Clinical Decision-Making for Immune Checkpoint Blockade  PDF
Suzanne L. Topalian, MD – Johns Hopkins University
9:15 am – 9:35 am Panel Discussion
9:35 am – 10:00 am Break
10:00 am – 11:40 am Session II: What does an “Immunologically Inert” Tumor Mean?
1.75 AMA PRA Category 1 Credit™
10:00 am – 10:20 am Genomic Approaches to Tumor Specific Immunotherapy
Robert D. Schreiber, PhD – Washington University
10:20 am – 10:40 am Molecular Mechanisms Controlling the T Cell-Inflamed Tumor Microenvironment: Implications for Therapy
Thomas F. Gajewski, MD, PhD – University of Chicago
10:40 am – 11:00 am Inducing T Cell Responses to Cancer by Providing Signal 0’s-DAMPs, PAMPs, and SAMPs and ‘Immunogenicity’
Michael T. Lotze, MD – University of Pittsburgh Cancer Institute
11:00 am – 11:20 am Effects of Targeted Therapies on the Immune System
Jennifer A. Wargo, MD – University of Texas, MD Anderson Cancer Center
11:20 am – 11:40 am Panel Discussion
11:40 am – 1:00 pm Lunch
1:00 pm – 2:40 pm Session III: How to Break Tumor-Induced Immune Suppression
1.75 AMA PRA Category 1 Credit™
1:00 pm – 1:20 pm Targeting Tregs in Tumors  PDF
Dario A. A. Vignali, PhD – University of Pittsburgh
1:20 pm – 1:40 pm Novel Checkpoint Targets that Bind Nectin and Nectin-Like Ligands
Ana Carrizosa Anderson, PhD – Harvard Medical School
1:40 pm – 2:00 pm Effects of Immunotherapy on the Tumor Microenvironment  PDF  VIDEO
Susan M. Kaech, PhD – Yale University
2:00 pm – 2:20 pm Molecular Mechanisms of T Cell Exhaustion  PDF  VIDEO
E. John Wherry, PhD – University of Pennsylvania
2:20 pm – 2:40 pm Panel Discussion
2:40 pm – 3:00 pm Break
3:00 pm – 4:45 pm Session IV: Ideas for Innovative Combination Approaches in the Future
1.75 AMA PRA Category 1 Credit™
3:00 pm – 3:20 pm Targeting Multiple Inhibitory Receptors to Reverse Melanoma-Induced T Cell Dysfunction
Hassane M. Zarour, MD – University of Pittsburgh
3:20 pm – 3:40 pm Cytokine and Anti-Angiogenesis Checkpoint Combinations
F. Stephen Hodi Jr., MD – Dana-Farber Cancer Institute
3:40 pm – 4:00 pm Imprecision Medicine: Combination Immunotherapy  PDF  VIDEO
Mario Sznol, MD – Yale University
4:00 pm – 4:45 pm Panel Discussion
4:45 pm – 5:00 pm Closing Remarks and Wrap-Up Summary
.25 AMA PRA Category 1 Credit™
Drew M. Pardoll, MD, PhD – Johns Hopkins University

 Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.